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The infectivity of HIV-1 virions can be enhanced by inhibition of the proteasome in target cells, leading to the hypothesis that the proteasome
degrades incoming virions as part of the intracellular antiviral defense. Here, several lines of evidence suggest instead that proteasome inhibition
renders target cells more susceptible to infection via an indirect effect on the cellular environment: (1) proteasome inhibition increased infectivity
more effectively when target cells were exposed to the inhibitors before exposure to virions, rather than when the inhibitors and virions were
present simultaneously; (2) increased infectivity correlated directly with the duration of pre-exposure of cells to the inhibitors; (3) although
increased infectivity was induced by as little as 30 min of pretreatment of target cells, binding of virions to target cells before the addition of
inhibitor abolished the effect; and (4) increased infectivity persisted after removal of the inhibitors and the recovery of proteasome activity
within the target cells. Cell cycle analyses revealed that an increased fraction of cells in G2/M may correlate with increased efficiency of
infection. These data suggest that rather than relieving a target cell restriction based on the degradation of incoming virions, proteasome
inhibitors likely increase infectivity either via their effects on the cell cycle or by increasing the expression of a host cell factor that facilitates
infection.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; Infectivity; ProteasomeSeveral studies have indicated that the inhibition of the
proteasome during the exposure of target cells to virions
increases the infectivity of HIV-1 (Schwartz et al., 1998; Wei et
al., 2005; Groschel and Bushman, 2005; Butler et al., 2002).
This effect was observed at the level of viral DNA accumulation
in target cells; it was robust to pseudotyping with the envelope
glycoprotein of vesicular stomatitis virus (VSV-G); and it was
detected using either CD4-positive HeLa cells or various CD4-
positive T cells lines as the targets of infection. The initial
interpretation of these results focused on the hypothesis that the
proteasome represents a host cell antiviral activity and that
inhibitors relieve a host-cell restriction based on the degradation
of incoming virions. However, two lines of evidence weigh
against this interpretation: (1) HIV-1 infectivity shows no⁎ Corresponding author. University of California, San Diego, 9500 Gilman
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doi:10.1016/j.virol.2007.01.018evidence of saturation of a host cell restriction factor at high
concentrations of inocula (Day et al., 2006); and (2) inhibition
of the proteasome has little or no influence when target cells are
arrested in G2/M, suggesting that the effect may be related to
perturbation of progress through the cell cycle (Groschel and
Bushman, 2005). To resolve the issue of whether inhibition of
the proteasome enhances viral infectivity via a direct effect on
incoming virions or via an indirect effect on the permissiveness
of target cells, we undertook a series of experiments designed to
characterize this effect with respect to the timing of exposure of
target cells to the inhibitors and to virus, and to determine
whether increased infectivity correlated with decreased protea-
some activity.
Results and discussion
Simultaneous exposure of HeLa-CD4 cells (clone P4.R5) to
HIV-1 virions and to the reversible peptide aldehyde proteasome
Fig. 1. Inhibition of the proteasome in target cells increases HIV-1 infectivity. (A) P4.R5 indicator cells (CD4-positive HeLa cells containing an LTR-β-galactosidase
sequence) were incubated with HIV-1NL4-3 (2.8 ng) for 5 h (with or without 25 μMMG-132) then washed and incubated at 37 °C. Two days later, the cells were stained
with X-gal. Blue cells indicate infectious centers. (B) P4.R5 cells were incubated with varying amounts of HIV-1NL4-3for 5 h (with or without 25 μMMG-132). Two
days later the cells were stained with X-gal and blue cells were counted. Each point represents the average of two measurements (error bars are the range of the data).
2 Rapid Communicationinhibitor MG-132 for 5 h increased infectivity approximately
2.5-fold over a broad range of inocula (Fig. 1, in which the virus
is the molecular clone NL4-3; Adachi et al., 1986). These results
corroborated previous data (Butler et al., 2002; Schwartz et al.,
1998; Wei et al., 2005; Santoni de Sio et al., 2006).
However, when the cells were pretreated with MG-132 for
5 h, followed by removal of the inhibitor before exposure to
virus, the increase in infectivity was even greater: approxi-
mately 6-fold with pretreatment of the cells compared to
approximately 3-fold with simultaneous treatment (Fig. 2A;
experiments using an NL4-3 derivative containing a bicistronic
GFP/Nef expression cassette at the 3′ end of the genome). The
relatively greater effect of pretreatment was observed over a
range of concentrations of MG-132 (Fig. 2B). This effect was
also observed using bortezomib, a boronic acid dipeptide that
also binds and inhibits the proteasome reversibly (Zavrski et al.,
2005), although the relatively greater effect of pretreatment was
less dramatic (Fig. 2B). MG-132 forms relatively unstable
adducts with the active sites of the β2 (trypsin-like) and β5
(chymotrypsin-like) catalytic subunits of the 20S proteasome; it
also inhibits calpains and cathepsin B (Zavrski et al., 2005).
Bortezomib is a specific inhibitor of the chymotrypsin-likeactivity of the β5 subunit, and it forms more stable (but
reversible) intermediates with the core of the 20S proteasome
(Zavrski et al., 2005). The relative effects of these compounds
seen in Fig. 2B may reflect these similar but not identical
mechanisms of action.
Strikingly, infectivity was directly correlated with the
duration of pretreatment of target cells with proteasome
inhibitor; the effect was detectable after 30 min of pretreatment
with MG-132 and increased with time for at least 5 h (Fig. 2C).
These observations suggested the possibility that the inhibition
of the proteasome might enhance infectivity by rendering target
cells more permissive for infection, rather than by relieving a
direct antiviral effect of the proteasome against incoming
virions. Consistent with this hypothesis, the effect of MG-132
was essentially abolished if the target cells were exposed to
virions at 4 °C before warming to 37 °C and adding MG-132 to
allow synchronous viral entry and proteasomal inhibition (Fig.
2D). Together, these results are most consistent with models in
which inhibition of the proteasome either allows target cells to
accumulate a specific factor that facilitates infection or induces
their accumulation at a specific stage of the cell cycle that
renders them more permissive.
Fig. 2. Pretreatment of target cells with proteasome inhibitors yields maximal increases in infectivity, whereas treatment concurrent with a pulse of viral entry is
ineffective. (A) P4.R5 cells were either pretreated with MG-132 (25 μM) or not for 5 h. Cells were then washed and exposed to HIV-1NL-EGFP (510 ng) for 5 h either
with (“Simultaneous”) or without (“Pretreat”) 25 μM MG-132. Cells were washed again and incubated at 37 °C. Two days later, the cells were analyzed by flow
cytometry for GFP fluorescence. (B) P4.R5 cells were either pretreated with the indicated concentrations of MG-132, bortezomib or nothing for 5 h. Cells were then
washed and exposed to HIV-1NL-EGFP (300 ng) with the indicated concentrations of MG-132, bortezomib or nothing for 5 h. Cells were washed again and incubated at
37 °C. Two days later, the cells were analyzed by flow cytometry for GFP fluorescence. Each point represents the average of two measurements (error bars are the
range of the data). (C) P4.R5 cells were pretreated with 25 μMMG-132 for varying periods of time (30 min, 1 h, 2 h or 5 h). Cells were then washed and incubated with
HIV-1 NL-EGFP (510 ng) for 5 h. Two days later, the cells were analyzed by flow cytometry for GFP fluorescence. Each point represents the average of two
measurements (error bars are the range of the data). (D) P4.R5 cells were chilled to 4 °C before the addition of HIV-1NL-EGFP (510 ng) and incubation at 4 °C for 2 h.
Cells were then washed with cold media and incubated with 25 μMMG-132 or drug-free media at 37 °C for 5 h (“virions pre-bound at 4 °C”). Cells were then washed
and incubated at 37 °C. Two days later, the cells were analyzed by flow cytometry for GFP fluorescence. As a control for the positive effect of MG-132 on infectivity,
virions and MG-132 (25 μM) were added simultaneously to cells at 37 °C for 5 h, before washing, incubation at 37 °C and analysis by flow cytometry 2 days later
(“virions and drug added at 37 °C”). Numbers are the average percentage of GFP+ cells in duplicate infections. “FS”: forward scatter. The results are representative of
two independent experiments.
3Rapid CommunicationTo rigorously test the hypothesis that proteasome inhibitors
block degradation of incoming virions, we compared the
kinetics of the recovery of proteasomal activity to the decay of
infectivity after removal of these reversible inhibitors. Recovery
of the proteasome was expected within 1 h after withdrawal of
MG-132 (Rock et al., 1994), so that any virologic effect
persisting after this time would not likely be due directly toinhibition of the proteasome. To confirm the expected kinetics of
proteasomal recovery, the activity of the proteasome within
target cells was measured using the substrate Suc-LLVY-AMC,
which fluoresces when cleaved by the chymotryptic-like activity
of the 20S proteasome (Stein et al., 1996). In this live cell assay,
proteasomal activity was detected within 15–30 min after the
addition of substrate (Fig. 3; compare “Cells but no drug” with
Fig. 3. Recovery of intracellular proteasome activity after removal of inhibitors. Left panel: P4.R5 cells were pretreated with MG-132 (25 μM) or nothing for 5 h. The
cells were then washed and exposed to 150 μM Suc-LLVY-AMC (with or without 25 μM MG-132) immediately or after a 2- or 5-h incubation. Right panel: P4.R5
cells were pretreated with bortezomib (1 μM) or nothing for 5 h. The cells were then washed and exposed to 150 μM Suc-LLVY-AMC (with or without 1 μM
bortezomib) immediately or after a 2- or 5-h incubation. Measurements were taken every 3 min in a fluorometer; the cells were maintained at 37 °C. Each point
represents the average of 3 measurements (C.V. <1% in all cases). “LLVY” is suc-LLVY-AMC.
4 Rapid Communication“No cells”). Inclusion of proteasome inhibitors during the assay
reduced the signal to the level of the controls from which cells
were omitted (compare “Simultaneous MG+LLVY” and
“Simultaneous bortez+LLVY” with “No cells”). Pretreatment
of cells for 5 h followed by removal of the inhibitors just before
the addition of substrate revealed recovery of activity by 45–
60 min. A delay of 2 or 5 h between pretreatment and the
addition of substrate resulted in nearly complete recovery of
proteosomal activity, which was almost indistinguishable from
untreated cells.
In contrast, pre-exposure of target cells to MG-132 or
bortezomib for 5 h induced a state of increased efficiency of
infection that was almost undiminished 2 h after removal of the
inhibitors and was still detectable 5 h after removal (Figs. 4A
and B). Together, the data of Figs. 3, 4A and B suggested that
the recovery of the proteasome markedly precedes reversion of
the cellular state of increased permissiveness for infection;
despite recovery of enzymatic activity within 45–60 min after
removal of inhibitor and essentially complete recovery after 2 h,
a state of increased permissiveness for infection persisted in
pretreated cells for at least 5 h.
The increased infectivity induced by inhibition of the
proteasome appears to reflect a state of increased target cellFig. 4. The cellular state of increased permissiveness for HIV-infection persists aft
cells were either pretreated with MG-132 (25 μM) or not for 5 h. Cells were then w
to HIV-1NL-EGFP (820 ng) for 8 h, washed and incubated at 37 °C. Two days later
cells were either pretreated with MG-132 (25 μM), bortezomib (1 μM) or nothing fo
were then exposed to HIV-1NL-EGFP (820 ng) for 8 h, washed and incubated at 37 °C.
Each point represents the average of two independent infections, one of which is show
in panel Awas used to derive the data. (C) The cells treated with MG-132 and analyze
propidium iodide to measure DNA content. These cell cycle analyses were performed
indicated within each representative histogram. The infectivity values are from the dpermissiveness that persists for several hours after recovery of
proteasomal activity. How might inhibition of the proteasome
alter the cellular milieu to facilitate infectivity? Inhibition of the
proteasome extends the half-life of many cellular proteins, with
the most dramatic effects on normally short-lived proteins.
Increased infectivity was detected within 30 min of pretreatment
with proteasome inhibitor (Fig. 2C), suggesting that if this effect
is due to an increase in the accumulation of a specific cellular
protein, then this protein is likely to have a very short half-life.
Notably, proteasome inhibitors enhance the infectivity of HIV-1
virions that are pseudotyped with VSV-G (Schwartz et al.,
1998), suggesting that this effect is not likely related to
increased expression of CD4 or co-receptors. Interestingly,
although increased infectivity is detectable within 30 min of
exposure of target cells to proteasome inhibitors, the effect is
not apparent when cells are exposed to inhibitor concurrent with
a pulse of viral entry (Fig. 2D). This observation suggests that
an early and committed step is modulated; apparently, this step
cannot be enhanced significantly even with the onset of the
more permissive cellular state by 30 min after viral entry.
Conceivably, viral entry itself could be the facilitated step; this
mechanism provides an explanation for the increased levels of
cytosolic p24 Gag detected in target cells treated wither removal of proteasome inhibitors; relationship to the cell cycle. (A) P4.R5
ashed and incubated at 37 °C for 0, 1, 2 or 5 h. The cells were then exposed
, the cells were analyzed by flow cytometry for GFP fluorescence. (B) P4.R5
r 5 h. Cells were then washed and incubated at 37 °C for 0, 1, 2 or 5 h. The cells
Two days later, the cells were analyzed by flow cytometry for GFP fluorescence.
n in panel A for MG-132 (error bars are the range of the data). Gate “D” as shown
d for infectivity in panel B were subjected to cell cycle analysis by staining with
on cells treated in duplicate; the average fraction of cells in G1, S and G2/M are
ata of panel B.
5Rapid Communicationproteasome inhibitors without requiring degradation of incom-
ing virions (Schwartz et al., 1998). Core uncoating or an
intracellular transport step could also be facilitated.An alternative to increased expression of a specific cell
factor is alteration of the cell cycle. Cell cycle regulators are
regulated by proteolysis mediated by the ubiquitin-proteasome
6 Rapid Communicationsystem (Peters, 1998; Gutierrez and Ronai, 2006). Conse-
quently, inhibition of the proteasome has several effects on the
cell cycle, including a block of G1/S and metaphase
transitions and delayed progression through S phase (Machiels
et al., 1997). Notably, the permissiveness of cycling target
cells to HIV-infection is enhanced in G2/M, and the enhancing
effect of certain cell cycle inhibitors on HIV infection and the
effect of MG-132 are not additive, suggesting a common
mechanism of action (Groschel and Bushman, 2005).
To test the cell cycle hypothesis, we correlated the effect of
proteasome inhibitors on the distribution of cells throughout the
cell cycle with their effect on infectivity. After 5 h of
pretreatment with MG-132, the fraction of cells in S and G2/M
was increased at the expense of the fraction in G1 (Fig. 4C).
After removal of the inhibitor, the fraction of cells in G1
decreased further over the next 5 h, while the fraction of cells in S
phase increased (Fig. 4C); similar results were obtained with
bortezomib (data not shown). These results excluded the fraction
of cells in G1 or S as correlates of increased permissiveness for
infection since infectivity decreased after removal of MG-132
(Figs. 4A and B). Interestingly, the fraction of cells in G2/M
increased from 14% to 20% with pretreatment, then declined to
an intermediate value of 17% 5 h after removal of the inhibitor;
these data are to an extent consistent with the effect on
infectivity, which increased from 19% to 74% with pretreatment
and declined to an intermediate value of 33% 5 h after removal of
the inhibitor. Although the absolute increase in infectivity
caused by proteasome inhibitors in these experiments (300% or
more in most cases) seems difficult to attribute to a 50% increase
in the number of cells in G2/M, it remains conceivable that
during the 5–8 h of exposure to virus the total fraction of cells
that have transited G2/M could be sufficiently increased by
proteasome inhibition to account for the infectivity effect.
The putative inhibitory effect of the proteasome on
infectivity could potentially underlie two phenomena in the
virology of HIV-1: restriction by TRIM5α and the CD4-
independent enhancement of infectivity by the accessory
protein Nef. Old World monkey TRIM5α restricts HIV-1 at a
post-entry step, and since some TRIM family proteins are
involved in ubiquitylation and proteasomal degradation, it
seemed plausible that the proteasome might mediate this effect
(Stremlau et al., 2004). However, it appears that inhibition of
the proteasome does not relieve restriction mediated by
TRIM5α (Stremlau et al., 2006). In the case of Nef, the
mechanism by which this protein enhances infectivity indepen-
dently of CD4 has been obscure, but very recent data suggest
that treatment of target cells with proteasome inhibitors
equalizes the infectivity of Nef-positive and Nef-negative
virions via a relatively greater effect in the absence of Nef (Qi
and Aiken, 2007). This result was interpreted to suggest that
Nef reduces the susceptibility of incoming virus particles to
proteasomal degradation in target cells. In view of the findings
herein, it seems more likely that proteasome inhibition would
increase the expression of a cellular factor such that the effect of
Nef on infectivity is rendered moot. However, we have not
observed loss of the Nef-effect by proteasome inhibition;
instead, we observed a similar relative increase in infectivitywhen either Nef-positive or Nef-negative virions were used
over a wide range of inocula to infect target cells treated with
MG-132 (data not shown).
In summary, we propose that the increased infectivity of
HIV-1 to target cells treated with proteasome inhibitors is not a
consequence of relief of a direct antiviral activity of the
proteasome. We cannot exclude an effect on the cell cycle,
specifically arrest in G2/M, as the basis for the virologic effect
of these inhibitors. Alternatively, the data are consistent with the
hypothesis that inhibition of the proteasome leads to the
accumulation of a cellular co-factor that facilitates a very early
event during viral replication.
Materials and methods
Cells
P4.R5 cells were obtained from Nathaniel Landau and
maintained in Dulbecco's modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), penicillin
(100 U/mL)–streptomycin (100 μg/mL) (pen/strep), 2 mM
L-glutamine and puromycin (1 μg/ml). HEK293T cells (also
from Nathaniel Landau) were maintained in complete medium
consisting of minimum essential medium (E-MEM) supple-
mented with 10% FBS, penicillin/streptomycin and
L-glutamine.
Proteasome inhibitors, cell treatments and substrate for
intracellular proteasome activity assays
“InSolution™ MG-132”, a 10-mM solution of MG-132
(Z-LLL-CHO) in DMSO, was purchased from Calbiochem
(#474791). Bortezomib (Velcade™; Millennium Pharmaceu-
ticals) was provided by the pharmacy of the San Diego
Veterans Affairs Healthcare System. After exposure to
proteasome inhibitors, cells were washed 3 times with
fresh media. Fluorogenic Proteasome Substrate III Suc-Leu-
Leu-Val-Tyr-AMC (Suc-LLVY-AMC) was purchased from
Axxora (#BST-S-280) and resuspended in DMSO.
Virus production
A plasmid encoding the complete proviral sequence of HIV-
1 clone NL4-3 (pNL4-3) and a pNL4-3 derivative expressing
GFP (pNL-EGFP) were used for the production of NL4-3 and
NL-EGFP viral stocks. pNL-EGFP encodes enhanced green
fluorescent protein 3′ of the env sequence, followed by an
internal ribosomal entry site and the nef sequence, and the
remainder of the 3′ long terminal repeat (LTR); this construct
was originated by Naoki Yamamoto and provided by Celsa
Spina. HEK293T cells were transiently transfected using
Lipofectamine 2000 (Invitrogen), 20 μg of plasmid DNA and
2 million cells plated in 100-mm-diameter tissue culture dishes.
Virus-containing supernatants were collected 2 days later,
centrifuged at low speed to pellet cells and cellular debris,
filtered (pore size, 0.2 μm) and then frozen at −80 °C. Prior to
freezing, all virus-containing supernatants were sampled for
7Rapid Communicationquantification of the p24 capsid protein by enzyme-linked
immunosorbent assay (ELISA).
P4.R5 infectious center assay
The P4.R5 cell line contains the β-galactosidase indicator
under the control of the HIV-1 LTR. Cells were plated at a
density of 2×104 cells per well in a 48-well tissue culture plate.
On the following day, cells were infected in duplicate with
100 μL of several dilutions of NL4-3 virus normalized by p24
capsid protein. After a 2-h incubation at 37 °C, the volume was
increased to 500 μL by adding 400 μL of complete medium.
After a 2-day incubation at 37 °C, cells were fixed with 1%
formaldehyde–0.2% glutaraldehyde in PBS. After washing
twice with PBS, cells were stained in an X-Gal (5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside) solution overnight
and finally washed again with PBS. Infectivity was measured
by counting the blue-stained, HIV-infected foci, using a digital
imaging system and computer software as described (Day et al.,
2006).
Measurement of infectivity by flow cytometry
P4.R5 cells were plated at a density of 8×104 cells per well in
a 12-well tissue culture plate. On the following day, cells were
infected in duplicate with 0.5 mL of NL-EGFP virus normalized
by content of p24 capsid protein. After a 5- or 8-h incubation at
37 °C the virus-containing media was aspirated and the cells
were washed 3 times with fresh media. After washing, 2 mL of
fresh media was added to each well. After a 2-day incubation at
37 °C, cells were detached using trypsin-EDTA, pelleted by low-
speed centrifugation and fixed in 0.5 mL of 1% paraformalde-
hyde in PBS. Cells were then analyzed for GFP fluorescence
using a flow cytometer.
Measurement of intracellular proteasome activity using
Suc-LLVY-AMC
P4.R5 cells were plated at a density of 3×104 cells per well
in clear-bottom, black-walled 96-well tissue culture plates. Cells
were incubated with 150 μL of 25 μM MG-132, 1 μM
bortezomib or drug-free media for 5 h at 37 °C. Cells were
washed 3 times with 200 μL of fresh media and then
replenished with 150 μL of fresh media. Cells were then
incubated for 0, 2 or 5 h at 37 °C. Media were then aspirated and
wells were loaded with 150 μL of 150 μM Suc-LLVY-AMC
with or without simultaneous MG-132 (25 μM) or bortezomib
(1 μM). Fluorescence measurements were obtained every 3 min
using a Tecan-Genios fluorometer (excitation=360 nm,
emission=465 nm, manual gain=50); the cells were maintained
at 37 °C throughout the experiment.
Measurement of DNA content and cell cycle determination by
flow cytometry
P4.R5 cells were treated or not with MG-132 as described in
the legend of Fig. 4 before fixation with 70% ethanol overnight,then stained with propidium iodide (50 μg/ml) for 30 min in the
presence of 10 μg/ml RNaseA in calcium- and magnesium-free
PBS before analysis by flow cytometry. Histograms of cell
number versus DNA-content were analyzed using Multi-
cycleAV software (Phoenix Flow, San Diego) to derive
estimates of the fraction of cells in G1, S and G2/M phases of
the cell cycle.
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